Archived page
National Cholesterol Education Program
Adult Treatment Panel III (ATP III) Guidelines Slide Set
SLIDE 1: ATP III Guidelines
Population Groups
SLIDE 2: Special Considerations for Different Population Groups
Younger Adults
- Men 20-35 years; women 20-45 years
- Coronary atherosclerosis accelerated by CHD risk factors
- Routine cholesterol screening recommended starting at age 20
- Hypercholesterolemic patients may need LDL-lowering drugs
SLIDE 3: Special Considerations for Different Population Groups (continued)
Older Adults
- Men greater than or equal to65 years and women greater than or equal to75 years
- High LDL and low HDL still predict CHD
- Benefits of LDL-lowering therapy extend to older adults
- Clinical judgment required for appropriate use of LDL-lowering drugs
SLIDE 4: Special Considerations for Different Population Groups (continued)
Women (Ages 45-75 years)
- CHD in women delayed by 10-15 years (compared to men)
- Most CHD in women occurs after age 65
- For secondary prevention in post-menopausal women
- Benefits of hormone replacement therapy doubtful
- Benefits of statin therapy documented in clinical trials
SLIDE 5: Special Considerations for Different Population Groups (continued)
Middle-Aged Men (35-65 years)
- CHD risk in men > women
- High prevalence of CHD risk factors
- Men prone to abdominal obesity and metabolic syndrome
- CHD incidence high in middle-aged men
- Strong clinical trial evidence for benefit of LDL-lowering therapy
SLIDE 6: Special Considerations for Different Population Groups (continued)
Racial and Ethnic Groups
- Absolute risk for CHD may vary in different racial and ethnic groups
Relative risk from risk factors is similar for all population groups - ATP III guidelines apply to:
- African Americans
- Hispanics
- Native Americans
- Asian and Pacific Islanders
- South Asians
Archived page, reproduced from a 2012 copy. It is reference material, not current guidance.